Vanguard Global Advisers
TVRD

Vanguard Global Advisers’s Tvardi Therapeutics TVRD Stock Holding History

Vanguard Global Advisers’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.46K Hold
3,400
– – ﹤0.01% 3532
2026
Q1 		$10.8K Buy
+3,400
New +$13.3K ﹤0.01% 3463

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Vanguard Global Advisers's TVRD Position: Q2 2026 in Review

Vanguard Global Advisers held its Tvardi Therapeutics (TVRD) position steady in Q2 2026 at 3,400 shares worth $6.46K. The position accounts for ﹤0.01% of the portfolio, ranked #3532.

Vanguard Global Advisers first reported a position in TVRD in Q1 2026 and has held it in 2 quarters since. The position peaked at $10.8K in Q1 2026. 57 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Vanguard Global Advisers held 3,400 shares of Tvardi Therapeutics worth $6.46K as of Q2 2026.
  • Vanguard Global Advisers left its Tvardi Therapeutics share count unchanged in Q2 2026.
  • Tvardi Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3532 holding.
  • Vanguard Global Advisers first reported a position in Tvardi Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Tvardi Therapeutics position peaked at $10.8K in Q1 2026.
  • 57 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.